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Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) 
(fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most 
common cause of the disease, accounting for around 20% of all families (ALS1) and 
isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have 
been reported to date. The possibility of a single founder and separate founders have 
been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations 
worldwide. High-throughput single nucleotide polymorphism genotyping studies have 
suggested two founders for A4V (one for the Amerindian population and another for the 
European population) although the possibility that the two populations are descended 
from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning 
the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them 
with the population reference panels, to demonstrate that the first A4V Spanish pedigree 
shared the genetic background reported in the European population.
Keywords: SOD1, A4V, p.A5V, amyotrophic lateral sclerosis, familial amyotrophic lateral sclerosis, ALS1, 
founder effect
INTRODUCTION
About 10% of amyotrophic lateral sclerosis (ALS) cases are familial (fALS), and genetics is the 
discipline that has made the greatest contribution to understanding the complexity of the disease’s 
pathogenesis, with a major impact on clinical practice, especially in the field of genetic counseling. 
Since the discovery of mutations in the SOD1 gene linked to ALS in 1993, an increasing number of 
genes have been reported as associated with the disease, justifying the term “genetic heterogeneity 
of ALS”. At least 31 major genes and 2 different genetic loci with dominant, recessive, and X-linked 
patterns of inheritance have been identified for fALS, and an increasing number of susceptibility 
or modifying gene loci have been suggested for fALS and several sporadic ALS (sALS) cases. The 
ALSoD database currently lists genetic variants in 126 genes as associated to ALS. Gene–gene and 
gene–environment interactions have also been suggested as playing a major role in the disease’s 
appearance and phenotype (Andersen and Al-Chalabi, 2011; van Blitterswijk et al., 2012; Abel et al., 
2013; Al-Chalabi et al., 2013; Leblond et al., 2014; Renton et al., 2014; Jones et al., 2015; Al-Chalabi 
et al., 2017; Brown and Al-Chalabi, 2017; Hardiman et al., 2017; van Es et al., 2017; Chia et al., 2018).
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Mutations in the gene encoding Cu/Zn superoxide dismutase 
(SOD1) are the second most common cause of fALS cases 
worldwide, accounting for approximately 20% of all families. 
ALS1 is the designation for fALS linked to the SOD1 gene (MIM 
105400). At least 186 different mutations in the SOD1 gene have 
been described, of which over 90% are missense, confirming its 
allelic heterogeneity (ALSoD1). The SOD1 mutations reported 
in ALS1 pedigrees are primarily associated with a dominant 
inheritance pattern and high penetrance, despite occasionally 
being found in apparently sporadic or recessive cases. Clinical 
heterogeneity, including gender predominance, age at symptom 
onset, site of onset, penetrance, and progression of the disease, has 
also been reported in many ALS1 families. The type of mutation 
and the resulting phenotype are strongly correlated in some cases 
(Andersen et al., 2003a; Andersen, 2003b; Andersen, 2006). 
However, information about the clinical–genetic correlations for 
most of these mutations is scarce. As a result, clinical and genetic 
data from families with ALS1 from around the world are being 
compiled in the constantly updated ALS database (ALSoD1). This 
database provides clinicians with information on research into 
the genetic characterization of ALS1 and other forms of familial 
ALS, as well as new candidate genes.
Epidemiological studies report that D90A is the most 
common mutation worldwide, although the most frequent 
mutation in North America is A4V (formally designated p.A5V, 
rs121912442), which accounts for 50% of North American ALS1 
families (ALSoD1, Watanabe et al., 2000; Andersen, 2003b; 
Andersen, 2006). The most striking features of the p.A5V 
mutation are rapid progression, with a mean survival time of 
less than 2 years from clinical onset, predominant lower motor 
neuron symptoms, and its rarity in the European population. 
The possibility of two founder haplotypes—one Native American 
and another European—has recently been suggested (Rosen, 
2004; Broom et al., 2008; Armon, 2009; Saeed et al., 2009; Tang 
et al., 2018). The p.A5V-SOD1 mutation has been described 
in a very small number of families in Europe, and never in the 
Spanish population.
Here we report the clinical characterization and high-
throughput single nucleotide polymorphism (SNP) genotyping 
of the first p.A5V (A4V) Spanish ALS kindred with high 
penetrance, predominant lower motor neuron involvement, fast 
progression, short survival times, and no cognitive impairment.
MATeRIAL AND MeTHODS
Subjects
This study was carried out following the protocol approved by the 
Hospital Universitari Vall d’Hebron Institutional Review Board 
with written informed consent from all subjects in accordance 
with the Declaration of Helsinki.
Our pedigree originated in north-western Spain. The simplified 
pedigree of the family is shown in Figure 1. We examined two 
ALS patients and two healthy individuals in the pedigree after 
1 http://alsod.iop.kcl.ac.uk/mutations/mutationsFoundGeneOnly.aspx?gene_
id=SOD1. Web site access on Oct 8th 2019.
obtaining informed consent. There were no skipped generations. 
The affected individuals were clinically characterized according 
to gender, age at onset, initial topography, signs of dementia, and 
survival time (Supplementary Table S1).
The proband, a 53-year-old male (II:1), noticed weakness in his 
left leg beginning 7 months previously, which he attributed to a 
traumatism he had experienced when working in construction. 
An initial electromyographic study showed denervation in all four 
extremities. Transcranial magnetic stimulation and brain and spinal 
MRI were normal. Cerebrospinal fluid, hemogram, biochemical 
screening, and serological tests for neurotropic infectious diseases 
all presented normal values, except for creatine kinase, which 
was 735 U/l (normal values < 135). The patient subsequently 
experienced pain, with frequent falls in the months after his first 
examination, when muscle strength in his upper limbs and right 
lower limb was completely normal. His Amyotrophic Lateral 
Sclerosis Functional Rating (ALSFRS-R) score was 44. In the 
next visit, 3 months later, we observed weakness and amyotrophy 
in the left upper limb, particularly in the proximal muscles. We 
observed generalized fasciculations, which were more marked 
in the muscles on the left side of the body, where it was difficult 
to elicit deep tendon reflexes. Eight months after the initial visit, 
the patient was admitted to the emergency ward complaining of 
dyspnea and orthopnea, and non-invasive mechanical ventilation 
was fitted. The patient was offered a gastrostomy, but declined. The 
patient died 19 months after symptom onset.
Two years later, the proband’s 47-year-old brother (II:5) 
came to our clinic due to presenting clumsiness and difficulties 
climbing stairs, running and walking. He had experienced 
recurring episodes of cramp in both calves in the 2 months before 
his visit. We observed weakness and amyotrophy in the proximal 
muscles of the right lower limb and a minimal loss of muscle 
mass in the first interosseous of the right hand. Deep tendon 
reflexes were normal, except for the patellar and Achilles reflexes. 
Fasciculation was observed in the musculature of the four 
extremities. His ALSFRS-R rating at this point was 39. Like his 
brother, neurophysiological studies showed signs of denervation 
in three regions and an absence of upper motor neuron signs. 
The patient declined any follow-up, life support, ventilation or 
nutritional measures. He died 17 months after clinical onset.
In their family, their two sisters requested genetic screening for 
familial forms of ALS, as they remembered that their father had 
died at 57 years of age due to respiratory insufficiency after 2 years 
of weakness in the upper limbs. To the best of our knowledge, this 
pedigree contains no other cases of neurodegenerative disorders, 
including frontotemporal dementia and Parkinson’s disease.
Genetic Studies
Selection of Single Nucleotide Polymorphisms for 
Analysis of the SOD1 Haplotype
In order to saturate the SOD1 region with genetic markers, we 
performed a scientific literature search of haplotypes previously 
described in the SOD1 gene. We consulted various databases (1K 
Genomes, dbSNP, and Ensembl Web sites) for SNPs in the SOD1 
region of the IBerian populations in Spain (IBS) population, and 
analyzed 14 SNPs and 1 repeat. Thirteen SNPs were selected from 
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the results of 79 A4V families (Broom et al., 2008) (rs4817415, 
rs2070422, rs1008270, rs9974610, rs2173962, rs4816405, 
rs2070424, rs1041740, rs2833475, rs16988427, rs2833481, 
rs2070423, rs2833483); and 1 additional SNP (rs202445) and a 
CA repeat from a study of 54 patients (Saeed et al., 2009) and 
genetic data from an isolated Chinese case (Tang et al., 2018). 
The locations of all markers and their previous designations are 
shown in Supplementary Table S2.
Genotyping of Normal and Mutant p.A5V  
Alleles in SOD1
The SNP rs121912442 (SOD1 p.A5V) region was amplified by 
PCR and the allele detected by Sanger sequencing. DreamTaq 
Master Mix was used under standard conditions according to the 
manufacturer’s instructions. Primer sequences and PCR cycling 
conditions are shown in Supplementary Table S3. PCR products 
were purified with ExoSAP-IT™ (Thermo Fisher Scientific Inc.) 
prior to automated Sanger sequencing using a BigDye® v3.1 
terminator Cycle Sequencing Kit in an ABI3730XL® (Thermo 
Fisher Scientific Inc., USA). DNA sequences were analyzed using 
the Finch TV 1.5.0 software.
Genotyping of Single Nucleotide Polymorphisms 
and Microsatellite
PCR Amplification of CA-repeat region was performed, and the 
products were analyzed by Sanger sequencing. The results were 
validated by Fragment Size Analysis using an ABI3730XL® system 
and GeneMapper 4.0 Software (Applied Biosystems). Most SNPs 
were genotyped by PCR amplification and Sanger sequencing 
as indicated above. In other cases, SNPs were detected by allele-
specific PCR using standard conditions and an internal PCR 
control. Their primers and annealing temperature are shown 
in Supplementary Table S3. PCR primers were designed using 
Primer3 version 4.0. (Untergasser et al., 2012).
The entire coding regions of SOD1, FUS, TARDBP, and 
PFN1 genes and the C9orf72 expansion were screened using 
Sanger sequencing.
Analysis of Data
LDhap software (Machiela and Chanock, 2015) was used with 
a 1K Genomes dataset to identify inferred haplotype blocks in 
the Iberian (IBS) population. Linkage disequilibrium between 
SNPs was calculated using LDMatrix software (LDLink). The 
SOD1 p.A5V haplotypes detected in our Spanish patients were 
compared with the haplotypes associated in American, Swedish, 
and Chinese populations (Broom et al., 2008; Tang et al., 
2018). The genetic data for the comparisons with the African 
(ACB, ASW, ESN, GWC, LWK, MSL, YRI), Asian (CHB, CHS, 
CDX, JPT, KHV), European (CEU, FIN, GBR, IBS, TSI), and 
Mixed American (CLM, MXL, PEL, PUR) populations were 
obtained from all the available subjects (n = 2,312 individuals 
from 19 populations, including 102 IBS subjects) of the 1K 
Genomes Project (phase 3, version 5) (The 1000 Genomes 
Project Consortium, 2015). Haplotype assembly was carried 
out by manual phasing of the alleles from the different 
variants analyzed.
ReSULTS
Clinical Characteristics of the p.A5V-SOD1 
pedigree
The clinical phenotype in the affected members in our family—a 
mean age of onset of 51.7 years, spinal onset, predominant lower 
motor neuron signs, and a survival time of 20 months—is consistent 
with the phenotype in the American, Italian, and Swedish families. 
No cognitive impairment in either brother was detected in the 
neuropsychological test (Supplementary Table S1).
FIGURe 1 | Pedigree of the family studied. The proband is indicated by an arrow (II:1). The haplotypes of the progenitors are inferred from the haplotypes of the 
offspring. Highlighted in red the genetic variation causing A5V mutation, in bold the single nucleotide polymorphisms that determine the differences between 
haplotypes of the IBS population. Haplotype (variation order): rs4817415, rs2070422, rs1008270, rs9974610, rs2173962, rs202445, rs121912442, rs4816405, 
Rs2070424, rs1041740, CA_repeat, rs2833475, rs16988427, rs2833481, rs2070423, rs2833483.
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Genetic Results
Mutation analysis of the SOD1 gene by direct PCR sequencing 
revealed a C-to-T transition at nucleotide position 14 (c.14C > T, 
Supplementary Figure S1) leading to a p.A5V (rs121912442, 
A4V in the old nomenclature) sequence change at protein level in 
the two affected ALS patients: the proband (individual II:1) and 
his brother (individual II:5) (Table 1). This exon 1 mutation was 
not found in the two healthy members of the family (individuals 
II:3 and II:4) who requested details of their genetic situation 
(Supplementary Figure S1).
No mutations were detected in the FUS, TARDBP, and PFN1 
genes, and no C9orf72 expansions were identified in the two 
ALS patients.
Haplotype Analysis
We analyzed the 15 genetic variants spanning the human 
chromosome 21 from the SOD1 gene to the SCAF4 gene 
(Supplementary Table S2). The genetic markers around the 
SOD1 gene were genotyped to infer the SOD1 haplotypes of the 
ALS patients and the family members. Based on the genotypes of 
the four siblings, it was possible to identify four different inferred 
haplotypes present in the family and propose the haplotypes of 
the affected father and the mother (Figure 1).
Fourteen of the 16 SNPs analyzed in the SOD1 gene 
were detected in subjects of the IBS population from the 1K 
Genomes Project. Eight phased haplotypes of the SOD1 region 
were inferred in the IBS population with different frequencies 
TABLe 1 | SOD1 p.A5V mutation founder haplotype in IBS population compared to other populations.
RS number SOD1 A5V founder haplotype patients genotype
USA* SWe* CHN** IBS II:1 II:5
rs4817415 C C − C C/C C/A
rs2070422 T C C C C/C C/C
rs1008270 A A − A A/A A/A
rs9974610 A A − A A/A A/A
rs2173962 T T − T T/T T/T
rs202445 - - − T T/T T/T
rs121912442 T T T T T/C T/C
rs4816405 G C C/G C C/C C/C
rs2070424 G A A A A/A A/A
rs1041740 C T C/T T T/T T/T
rs2833475 G A A A A/A A/A
rs16988427 C T T/C T T/T T/T
rs2833481 C T T T T/T T/T
rs2070423 T C C/T C C/C C/C
rs2833483 C T T/C T T/T T/T
*Data from Broom et al., 2008. **Data from Tang et al., 2018. (-) Not available.
FIGURe 2 | Haplotypes inferred in the IBS population (1K Genomes Project). The IBS haplotype_ID codification is based on the frequency of the haplotype in the 
IBS population, and in the case of the most frequent (IBS haplotype_ID = 1) the presence of the SOD1 p.A5V protein mutation (1V). (*) The haplotype 1V and allele 
rs121912442T are only present in the Spanish ALS patients with the SOD1 p.A5V mutation.
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(Figure 2). The haplotypes were named (1 to 8) according to 
their frequency in the population, ranging from higher to lower 
frequency (Figure  2). The mutation p.A5V-SOD1 detected in 
the ALS patients is only compatible with haplotype 1 (haplo1V), 
which is the most common in the IBS population (haplo1A) 
(Figure 2 and Table 1). According to the nomenclature proposed, 
the family has the IBS haplotypes 1A, 1V, 4, and 1A* (Figure 1).
The linkage disequilibrium of these 14 SNPs was calculated 
for the IBS population (Supplementary Figure S2). A 
conserved haplotype block, in high linkage disequilibrium, 
was detected between the start of intron 1 and the end of SOD1, 
and including the SCAF4 gene. The SOD1 exon 1, including the 
c.14C > T (p.A5V) mutation, is located outside this conserved 
haplotype in the IBS population (Supplementary Figure S2). 
Using data for all the populations deposited in the 1K Genomes 
Project, the analysis of linkage disequilibrium showed the 
same results for the conservation of this SOD1 haplotype block 
(data not shown).
The founder p.A5V-SOD1 haplotype in our patients is the 
same as the one found in the Swedish population, and differs 
from the founder haplotype observed in patients from North 
America (Table 1).
We determined all the inferred SOD1 haplotypes for these 
14 SNPs in the IBS, European, Asian, African, and Mixed 
American populations, using all the available subjects from 
the 1K Genomes Project as a control group (Figure 3). A 
total of 21 phased inferred haplotypes were detected in all the 
populations. The European haplotype (p.A5V-EUR) was the 
most common in all the populations. The American haplotype 
(p.A5V-USA) was the second most common worldwide. 
However, both haplotypes appear with similar frequencies in 
the Asian population (0.386 for p.A5V-EUR, 0.385 for p.A5V-
USA) (Figure 3).
DISCUSSION
Redefining the p.A5V-SOD1 phenotype. 
Reasons for the Disease’s Aggressive 
Course
Over 186 SOD1 mutations have been reported in amyotrophic 
lateral sclerosis (ALSoD). Previous epidemiological studies 
suggest that p.D91V is the most common worldwide, followed 
by p.I113T and p.A5V. The latter is the most commonly 
reported in the United States, accounting for 41% of the 
mutations identified in that population. It is one of the most 
aggressive mutations, as the mean survival time is under 2 
years. The mutation has rarely been described among European 
populations. This is the first time that the p.A5V-SOD1 has 
been reported in the Spanish population.
With the rare exception of a 73-year-old male presenting 
facial diplegia and unilateral vocal cord paralysis as the initial 
symptoms of ALS (Salameh et al., 2009), the phenotype associated 
with p.A5V in the American population is characterized by rapid 
progression and short survival. Patients present predominantly 
lower motor neuron signs, with limb weakness in 51% of patients, 
and bulbar symptoms in less than 11% of cases (Cudkowicz 
et al., 1997; Juneja et al., 1997; Andersen, 2003b; Andersen, 2006; 
Broom et al., 2008; Saeed et al., 2009). In a recent review of 57 
p.A5V-SOD1 cases, the mean survival time was 1.4 years, with 
clinical onset at a mean age of 50.0 years, and a male-female 
ratio of 1.3:1. Other characteristics associated with this SOD1 
mutation include fast progression, predominantly spinal onset, 
high penetrance, involvement of primarily lower motor neuron 
signs, and an absence of dementia (Bali et al., 2017).
However, the cases reported in European families differ 
slightly from those in America. For example, Andersen reported 
the clinical characteristics of a Swedish family (Andersen et al., 
FIGURe 3 | Inferred haplotypes around the SOD1 gene detected in all populations from the 1K Genomes Project. (A) 21 inferred haplotypes. (B) Haplotype 
frequencies and counts are shown for each subpopulations: African (ACB, ASW, ESN, GWC, LWK, MSL, YRI); European (CEU, FIN, GBR, IBS, TSI); East Asian 
(CHB, CHS, CDX, JPT, KHV); South Asian (GIH, PJL, BEB, STU, ITU); Mixed American (CLM, MXL, PEL, PUR); all (African + European + East Asian + South Asian + 
Mixed Americans). EUR, haplotype base for p.A5V-EU. USA, haplotype base for p.A5V-USA.
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1997; Andersen, 2007). One case had leg onset, another had hand 
onset, another had shoulder onset, and a further case had bulbar 
onset. These individuals were aged between 56 and 68 years old, 
and survival ranged from 8 months to 2 years. In the members 
of the two Italian families reported in 2001, information was 
available for two probands. One had shoulder onset at 55 years 
old, and died 8 months later. The other proband presented hand 
onset at 57 years old. No information about this individual’s 
survival time is available, although the course was rapidly 
progressive (Gellera et al., 2001). Our family’s phenotype—a 
mean age of onset of 51.7 years, spinal onset, predominant lower 
motor neuron signs, no cognitive alteration, and a survival 
time of 20 months—is consistent with the phenotype in these 
European families. Interestingly, none of the women inherited 
the mutation. Whether this was due to chance or a protective 
factor is unknown.
The reasons why p.A5V-SOD1 predicts fast progression and 
short survival are unknown. In vitro studies have pointed to this 
mutation leading to a decline in dimerization capacity, a loss 
of metalation (a 30-fold decrease in zinc-binding affinity), and 
aberrant oligomerization, leading to misfolding and aggregation 
in the form of insoluble toxic inclusions within motor system 
cells, a key pathological hallmark of ALS. There is some 
variability in the propensity of SOD1 mutants to aggregate, which 
could be related to the duration of the disease. High-aggregation 
propensities have been described for p.A5V, which could be the 
factor responsible for the disease’s short duration (Prudencio 
et al., 2009; Zhao et al., 2014; Farrawell et al., 2018; Maurel et al., 
2018; Srinivasan and Rajasekaran, 2018).
Another alternative and complementary hypothesis to 
explain the aggressive nature of p.A5V is its position in the 
tertiary structure of the protein. Interestingly, of the 30 mutations 
reported in exon 1, most of those in residue A5 (A4 in the previous 
nomenclature) predispose to a rapid progression and survival of 
under 24 months (Syriani et al., 2009). According to the tertiary 
structure of SOD1, residue A5 is located in the first β-strand that 
forms part of the dimer interface. A5 mutations affect SOD1 
dimerization and/or destabilize the Greek key β-barrel because 
A5 packs into the SOD1 monomer’s hydrophobic core (Getzoff 
et al., 1990; Deng et al., 1993; Cardoso et al., 2002; Galaleldeen 
et  al., 2009; Schmidlin et al., 2009; Schmidlin et al., 2013; 
Kumar  et al., 2018).
Founder effect
Two earlier studies investigated a possible founder effect in 
the cases of North American and European origin. Following 
these haplotype studies, there is evidence to suggest at least 
two different origins: one European (probably a Scandinavian 
founder effect) and one Amerindian (Native Americans). The 
latter presents in 82% of North American families with the 
p.A5V-SOD1 mutation. In European populations, p.A5V-SOD1 
has been reported in Scandinavia (three cases) and Italy (six 
cases). An isolated case has recently been reported in China, 
which shares most of the European haplotype. These findings 
could be interpreted in terms of the existence of various founders 
for p.A5V patients worldwide, rather than one founder, as 
previously assumed (Broom et al., 2008; Saeed et al., 2009). Some 
authors suggest that the European founder effect is older than the 
Amerindian, hypothesizing that the American families were in 
fact descendants of the European founder. Other authors argue 
that the European origin is different from the American one 
(Rosen, 2004; Armon, 2009).
After analyzing the SOD1 haplotypes in different populations 
(European, Asian, African, and all the populations analyzed in 
the 1K Genomes Project), we found that the SOD1 haplotype in 
which the p.A5V mutation is located in European fALS patients 
(p.A5V-EU) is the most common in the population worldwide, 
and the haplotype for American p.A5V-SOD1 patients (p.A5V-
USA) is the second most common. These variants appear to be 
linked to the most common haplotypes, and not linked to rare 
haplotypes. The haplotype p.A5V-USA is the most common 
(0.385) in the East Asian population and the p.A5V-EU haplotype 
is the second most common (0.306), with little difference between 
their allelic frequencies. However, in the European population, 
the haplotype p.A5V-EU is the most common haplotype (0.298), 
far below the frequency of the haplotype p.A5V-USA (0.062). 
The haplotypes p.A5V-EU (0.037) and p.A5V-USA (0.045) are 
rare in the African populations (as shown in Figure 3).
Based on these data, we propose two possible hypotheses for 
the origin of this mutation in two different haplotypes:
A Single Origin for All p.A5V-SOD1  
Families Worldwide
Information from previous linkage analyses suggests an 
origin for p.A5V around 13,000 years ago, probably in Asia. 
The p.A5V mutation appears in the p.A5V-EU haplotype and 
would have disseminated in Europe and Asia. A homologous 
recombination could have occurred in an ALS American family, 
leading to the linkage of the p.A5V mutation to the p.A5V-USA 
haplotype. A founder effect in North America could explain 
the p.A5V mutation associated to the p.A5V-USA haplotype in 
most (82%) cases in the American families (Rosen et al., 1994; 
Rosen, 2004; Broom et al., 2008; Armon, 2009; Saeed et al., 
2009) and to the p.A5V-EU in only 18% of the other fALS cases. 
Only the p.A5V mutation linked to the haplotype p.A5V-EU 
is detected in Asia and Europe. Interestingly, linkage analysis 
of the haplotype of SOD1 SNPs, a highly conserved haplotypic 
block (with a strong correlation) is observed after exon 1, but 
does not contain exon 1.
Several Origins (One for Asians, One for Americans, 
and Perhaps One or More for Europeans)
Previous studies investigating the haplotypic region around 
SOD1 have suggested different mutational events to explain 
the mutation in USA and European ALS patients (Rosen, 2004; 
Broom et al., 2008, Eisen et al., 2008; Saeed et al., 2009). It is 
possible that the mutation in A5 was generated in the haplotypes 
p.A5V-USA and p.A5V-EU independently, since the two 
haplotypes are the most frequent in the population worldwide, 
and the locus at codon 5 of SOD1 would be prone to mutations 
(a hotspot) since four additional mutations (p.A5T, p.A5S, p.A5F, 
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and p.A5P) have been described in this codon (Syriani et al., 
2009; Pratt, 2014).
From the molecular point of view, the most parsimonious 
hypothesis would be a single origin for the A5V mutation. 
Our hypothesis of a common founder for p.A5V is supported 
by research investigating who first colonized America and 
when they did so. These genetic studies showed that the first 
inhabitants of the Americas came from a single Siberian 
population, who used the Bering Land Bridge to migrate from 
Beringia to the Americas sometime after 16,500 years ago 
(Bonatto and Salzano, 1997; Goebel et al., 2008). We propose 
a Eurasian origin for the A5V mutation in the haplotype 
p.A5V-EU. A Eurasian individual could have introduced the 
A5V mutation of the haplotype p.A5V-EU in America, and 
the mutation could have recombined in their descendants to 
obtain the p.A5V-USA haplotype linked to the p.A5V mutation. 
A genetic drift in America could therefore explain the founder 
effect of p.A5V in the haplotype p.A5V-USA being the most 
frequent ALS1 mutation in USA. A similar genetic phenomenon 
was described for the D90A mutation. Initial studies proposed 
two different founder effects (one for heterozygous cases and one 
for homozygous cases) (Al-Chalabi et al., 1998). After increasing 
the sample set and the markers, they concluded that there was 
a single founder for all cases. These studies for this mutation 
showed that the D90A mutation arose in Eurasia approximately 
20,000 years ago (Parton et al., 2002).
Asian or Amerindian origins have been proposed for the 
A5V mutation based on their high frequency in USA and the 
haplotype p.A5V-USA being the most frequent haplotype in 
Asian populations (Rosen 2004; Broom et al., 2008; Saeed et al., 
2009). The hypothesis of these two origins (Amerindian and 
Asian) is contradicted by the failure to detect the A5V mutation 
in the p.A5V-USA haplotype in ALS cases from Africa, Europe, 
Asia, and among Native Americans. Current data, including 
our results, indicate that the A5V mutation cases have been 
associated to the p.A5V-EU haplotype in different populations 
from Europe, USA, and Asia.
The SOD1 haplotypes inferred from the IBS population 
enabled us to identify the haplotypes of the four members of 
a Spanish ALS family of Caucasian origin with two affected 
brothers with the p.A5V-SOD1 mutation. The SOD1 haplotype 
associated to the A5V mutation in our Spanish cases is the 
most frequent in the IBS and European populations. To our 
knowledge, our Spanish family is unrelated to the other p.A5V 
reported cases from Sweden (three subjects from one family) or 
Italy (six subjects from two families). A more detailed haplotype 
analysis of the European fALS cases with this mutation will be 
necessary to investigate whether there is a common origin for 
the p.A5V-SOD1 mutation in the European ALS cases, or if it is a 
consequence of different mutational events. This research could 
be carried out through an international collaborative consortium 
to enroll and analyze these ALS families, as in the study suggested 
by an Italian group (Gellera et al., 2001).
In conclusion, this is the first report on the p.A5V-SOD1 
mutation in the Spanish population. The age at onset, 
site of  onset, and survival were similar to those reported 
mainly  in  North American kindreds, in a few European 
families and in one Asian individual. SNP and haplotype 
analyses identify 21 haplotypes worldwide for the SOD1 
genomic region. Our family shares the haplotype reported in 
the founder European effect rather than the more frequent 
Amerindian haplotype.
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